Hover over a term you want explained. If you need more details, then click on the term and a new tab will open with a full details page.
Autohomologous Immunotherapy, often called AHIT, is a treatment approach that uses a patient’s own immune cells or biological material to help fight disease. The word "autohomologous" means the cells or substances come from the same person receiving the treatment, not from a donor. In practice, immune cells or blood components are collected from the patient, sometimes modified or activated outside the body, and then returned to help the immune system better recognize and attack harmful cells like cancer cells. This method aims to boost the body’s natural defenses rather than directly killing cancer cells with drugs or radiation.
AHIT is part of a larger group of treatments called immunotherapies, which work by supporting the immune system’s ability to fight cancer. Unlike standard cancer treatments such as chemotherapy or radiation, which attack cancer cells directly, AHIT tries to strengthen the immune system’s natural response. Because the cells used come from the patient, there is usually a lower risk of rejection or serious immune reactions compared to treatments using donor cells. However, AHIT is not widely used in mainstream cancer care and is often considered experimental or complementary. It may be offered in clinical trials or specialized treatment plans when other treatments are not enough or to support the immune system.
Patients may hear about AHIT during discussions of immunotherapy options or when reviewing treatment plans that include personalized immune-based therapies. The term might appear in medical records, clinical trial descriptions, or alternative therapy literature. Some versions of AHIT involve processing the patient’s biological material with ozone, a form of oxygen therapy, which is not part of standard cancer immunotherapy. Because of this, AHIT may be mentioned in complementary or alternative medicine contexts rather than mainstream oncology. It is important for patients to ask their care team what AHIT means in their specific case, how it works, and what to expect from the treatment.
AHIT should not be confused with other immune-related conditions or treatments that have similar abbreviations. For example, autoimmune heparin-induced thrombocytopenia (also abbreviated aHIT) is a rare immune reaction affecting blood platelets and is unrelated to autohomologous immunotherapy. Additionally, AHIT is different from well-known cancer immunotherapies like checkpoint inhibitors or CAR-T cell therapy, which have more established roles in cancer treatment. Understanding that AHIT uses the patient’s own cells or material helps set realistic expectations about its benefits and risks.
If AHIT is mentioned as part of your care, it is helpful to ask your healthcare providers about the goals of this therapy, how it fits into your overall treatment plan, and what evidence supports its use. You might also want to know about possible side effects, how the treatment is given, and whether it is part of a clinical trial or an alternative therapy. Clear communication with your care team can help you understand whether AHIT is appropriate for your situation and what to expect.
Seeing the term AHIT in your medical information does not automatically mean you will receive this therapy. It is one option among many immune-based treatments and may not be suitable or available for every patient. AHIT is a complex and evolving area of medicine, and its use depends on factors like the type of cancer, your overall health, and other treatments you may be receiving. It is best understood as a personalized approach aimed at supporting the immune system rather than a guaranteed cure.
This information about AHIT is educational and does not replace medical advice. Treatment decisions should always be made with your healthcare providers, who understand your unique situation. If you hear about AHIT in your care, the next sensible step is to discuss it openly with your doctor or nurse. Ask how it might apply to your treatment, what the process involves, and whether there are clinical trials or other options available. This will help you feel more confident and informed as you navigate your cancer care journey.
Public source information used for this glossary entry includes: